Search results
Results From The WOW.Com Content Network
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin bladder cancer: GDP gemcitabine, dexamethasone, cisplatin: Non-Hodgkin lymphomas and Hodgkin lymphoma: GemOx or GEMOX: gemcitabine, oxaliplatin: Non-Hodgkin lymphomas: GVD: gemcitabine, vinorelbine, pegylated liposomal doxorubicin: Hodgkin lymphoma: GemOx-R or GEMOX-R or R-GemOx ...
Gemcitabine is a chemotherapy drug that works by killing any cells that are dividing. [11] Cancer cells divide rapidly and so are targeted at higher rates by gemcitabine, but many essential cells also divide rapidly, including cells in skin, the scalp, the stomach lining, and bone marrow, resulting in adverse effects. [17]: 265
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) in a standard regimen.
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...
Most major toxicities of cisplatin, especially nephrotoxicity, were also reduced in the group of patients treated with lipoplatin and treatment did not require hospitalisation for lipoplatin patients. Median survival times were 10 months for the lipoplatin arm and 8 months for the cisplatin arm, with a ‘’p’’-value of 0.155.
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...